Discover
GOSS
Gossamer Bio, Inc.
0.17
4 x 0.16
2 x 0.16
bid
ask
+
0.00
1.88%
3 @ 04:00 PM
0.17 +0.01 (3.64%)
| Ytd | -94.59% | |
| 1y | -86.58% |
0.16
day range
0.17
0.14
52 week range
3.87
| Open | 0.17 | Prev Close | 0.16 | Low | 0.16 | High | 0.17 | Mkt Cap | 81.98M |
| Vol | 11.30M | Avg Vol | 11.93M | EPS | -0.79 | P/E | N/A | Forward P/E | -1.24 |
| Beta | 1.96 | Short Ratio | 6.29 | Inst. Own | 77.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 0.25 | 200-d Avg | 1.66 | 1yr Est | 7.61 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.18 | -0.14 | 0.04 | 22.22% |
| 2024-08-12 | 2024-06 | 0.23 | 0.22 | -0.01 | -4.35% |
| 2024-08-12 | 2024-06 | 0.23 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.19 | -0.19 | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.19 | N/A | N/A | N/A |
| 2024-03-05 | 2023-12 | -0.2 | -0.21 | -0.01 | -5.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-06-25 | Oppenheimer | Upgrade | Outperform | |
| 2024-06-17 | Goldman Sachs | Upgrade | Buy | Buy |
Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-23 | ARANDA RICHARD | Officer | 199.43K | Sale |
| 2023-03-15 | CARTER LAURA | Officer | 76.26K | Sale |
| 2024-03-26 | CHRISTIAN WAAGE | Officer | 654.05K | Sale |
| 2024-06-17 | GIRAUDO BRYAN M. | Chief Operating Officer | 0.00 | Purchase |
| 2024-03-26 | HASNAIN FAHEEM | Chief Executive Officer | 5.16M | Sale |
| 2023-11-14 | MILLIGAN SANDRA | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | NEA Management Company, LLC | 18.09M | 15.52M | 7.98% |
| 2024-09-29 | Siren, L.L.C. | 13.28M | 11.40M | 5.86% |
| 2024-09-29 | Vanguard Group Inc | 11.75M | 10.09M | 5.19% |
| 2024-09-29 | Octagon Capital Advisors LP | 9.19M | 7.88M | 4.05% |
| 2024-09-29 | Arch Venture Management, Llc | 8.06M | 6.91M | 3.56% |
| 2024-09-29 | FMR, LLC | 7.94M | 6.81M | 3.50% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 7.91M | 6.79M | 3.49% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 7.84M | 6.73M | 3.46% |
| 2024-07-30 | Federated Hermes Kaufmann Small Cap Fund | 3.07M | 2.63M | 1.35% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 2.88M | 2.47M | 1.27% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 1.08M | 926.99K | 0.48% |
| 2024-08-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 941.45K | 807.76K | 0.42% |